Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Culture

21 Apr 2023

ESPN Documentary Looks at Psychedelic Treatments For Athletes

Feeling empowered by the growing public support and diminishing social stigma, a steady stream of celebrities are opening up about mental health and the positive effects of psychedelics on their...

By Microdose NewsDesk

Industry

18 Apr 2023

Atai Partner IntelGenx Announces FDA Approval of Oral Film

Under-the-radar firm IntelGenx has just received FDA approval....

By Microdose NewsDesk

Don’t Miss

17 Apr 2023

News You Might Have Missed: April 17th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk

Industry

14 Apr 2023

MindMed Announces Positive Data from Phase 2 LSD Trial for Depression

One of MindMed’s most valuable assets is its deal with the University Hospital Basel and its research team led by Dr....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Law & Politics

13 Apr 2023

Hawaii Passes Bill To Prepare For Federal Approval of Psychedelics

Psychedelic legislation is moving through the Aloha state....

By Microdose NewsDesk

Industry

11 Apr 2023

Numinus Launches New Clinic Licensing Platform

It’s been a tough time for patients in need of psychedelic therapy....

By Microdose NewsDesk

Law & Politics

10 Apr 2023

Bipartisan Group Pushes Congress for Psychedelic Research

We write to support language in the Labor, Health and Human Services, Education, and Related Agencies appropriations bill for Fiscal Year 2024 to strongly urge the National Institutes of Health...

By Microdose NewsDesk

Don’t Miss

10 Apr 2023

News You Might Have Missed: April 10th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk

Industry

6 Apr 2023

Ketamine Wellness Centers Re-Opening? Delic Holdings Signs LOI with Peter/PetraMD

We've been covering how recent closures of ketamine clinics have left patients without crucial mental health treatments....

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.